One such HSP90-antagonist, GA, has been studied in stroke models with salutary results [113], but has failed at the clinical level due to poor solubility in water [115] and to unacceptable renal and hepatic toxicity [116,117]. This evidence concerns the gene HSP90AA1 and Stroke.